GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AC Immune SA (NAS:ACIU) » Definitions » EV-to-FCF

ACIU (AC Immune) EV-to-FCF : 2.86 (As of Dec. 12, 2024)


View and export this data going back to 2016. Start your Free Trial

What is AC Immune EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, AC Immune's Enterprise Value is $133.33 Mil. AC Immune's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $46.69 Mil. Therefore, AC Immune's EV-to-FCF for today is 2.86.

The historical rank and industry rank for AC Immune's EV-to-FCF or its related term are showing as below:

ACIU' s EV-to-FCF Range Over the Past 10 Years
Min: -134.49   Med: -2.69   Max: 36.97
Current: 2.86

During the past 10 years, the highest EV-to-FCF of AC Immune was 36.97. The lowest was -134.49. And the median was -2.69.

ACIU's EV-to-FCF is ranked better than
55.84% of 385 companies
in the Biotechnology industry
Industry Median: 8.82 vs ACIU: 2.86

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-12), AC Immune's stock price is $2.99. AC Immune's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.459. Therefore, AC Immune's PE Ratio (TTM) for today is At Loss.


AC Immune EV-to-FCF Historical Data

The historical data trend for AC Immune's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AC Immune EV-to-FCF Chart

AC Immune Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.92 -1.74 -2.71 -0.52 -5.38

AC Immune Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.27 -5.38 -3.64 4.24 4.10

Competitive Comparison of AC Immune's EV-to-FCF

For the Biotechnology subindustry, AC Immune's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AC Immune's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AC Immune's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where AC Immune's EV-to-FCF falls into.



AC Immune EV-to-FCF Calculation

AC Immune's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=133.327/46.693
=2.86

AC Immune's current Enterprise Value is $133.33 Mil.
AC Immune's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $46.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AC Immune  (NAS:ACIU) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

AC Immune's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.99/-0.459
=At Loss

AC Immune's share price for today is $2.99.
AC Immune's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.459.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


AC Immune EV-to-FCF Related Terms

Thank you for viewing the detailed overview of AC Immune's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


AC Immune Business Description

Traded in Other Exchanges
Address
EPFL Innovation Park, Building B, Lausanne, CHE, 1015
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.